

**DECLARATION FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION, the specification of which:

- ☐ is attached hereto.  
☒ was filed on August 21, 1997 as Application Serial No. 08/915,918.  
☐ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)Priority Claimed

☐ Yes ☐ No

(Number)	(Country)	(Day/Month/Year Filed)
<u>60/024,980</u>		<u>August 30, 1996</u>
(Application Serial No.)		(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)	(Filing Date)	(Status-patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's Signature

*S. Efendic*

Date: 9/11/24

Full name of sole or first inventor

Suad Efendic

Residence

Stjarnvagen 16B, 18134 Lidingo, Sweden

Citizenship

SWEDEN

Post Office Address

Stjarnvagen 16B, 18134 Lidingo, Sweden

Inventor's Signature

Date:

Full name of second joint inventor, if any

Residence

Citizenship

Post Office Address

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200

**BEST AVAILABLE COPY**

# CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By Valerie A. Wilson ELI LILLY AND COMPANY Date February 17, 2000

## PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Suad Efendic	)	
Serial No.	:	08/915,918	)	
Filed	:	August 21, 1997	)	Group Art Unit:
			)	1646
For	:	USE OF GLP-1 ANALOGS IN TREATMENT	)	
		OF MYOCARDIAL INFARCTION	)	Examiner:
Docket No.	:	X-10822	)	Saoud, C.

### POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST (REVOCATION OF PRIOR POWERS)

Assistant Commissioner for Patents  
Washington, D. C. 20231

Sir:

I, Robert A. Armitage, Vice President and Patent Counsel, LRL Law of Eli Lilly and Company, am authorized to sign this Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers) on behalf of Eli Lilly and Company which is the Assignee of record of the Entire Interest of the above-identified patent.

The Assignee hereby revokes all powers of attorney previously given, and hereby appoints

<u>Attorney</u>	<u>Reg. No.</u>	<u>Attorney</u>	<u>Reg. No.</u>
Arvie J. Anderson	45,263	Francis O. Ginah	44,712
Lynn D. Apelgren	845,341	Edward P. Gray	30,638
Robert A. Armitage	27,417	Amy E. Hamilton	33,894
Brian P. Barrett	39,597	Suzanne M. Harvey	42,640
Michael T. Bates	34,121	Frederick D. Hunter	26,915
Roger S. Benjamin	27,025	Thomas E. Jackson	33,064
William R. Boudreaux	35,796	Charles Joyner	30,466
Steven P. Caltrider	36,467	James J. Kelley	41,888
Paul R. Cantrell	36,470	Paul C. Kimball	34,641
Charles E. Cohen	34,565	Paul J. Koivuniemi	31,533
Kenneth J. Collier	34,982	Robert E. Lee	27,919
Daniel W. Collins	31,912	James P. Leeds	35,241
Robert A. Conrad	32,089	Nelsen L. Lentz	38,537
Elizabeth A. Dawalt	44,646	Ronald S. Maciak	35,262
Paul R. Darkes	33,862	Janet T. McClain	36,863
Steven G. Davis	39,652	Scott A. McNeil	37,185
John C. Demeter	30,167	Arlene K. Musser	37,895
Manisha A. Desai	43,585	Douglas K. Norman	33,267
John H. Engelmann	28,075	Arleen Palmberg	40,422
Joanne Longo Feeney	35,134	Raymond S. Parker III	34,893
Paul J. Gaylo	36,808	Thomas G. Plant	35,784

BEST AVAILABLE COPY

Serial No. 08/915,918

James J. Sales	33,773
Michael J. Sayles	32,295
Robert L. Sharp	P45,609
David M. Stemerick	40,187
Mark J. Stewart	43,936
Robert D. Titus	40,206
Barbara Twardzik	36,386

MaCharri Vorndran-Jones	36,711
Gilbert T. Voy	43,972
Andrea C. Walsh	34,988
Thomas D. Webster	39,872
Lawrence T. Welch	29,487
Alexander Wilson	P45,782

to prosecute and transact all business in the Patent and Trademark Office connected with the above-identified patent.

Please send correspondence in connection with this application to:

Eli Lilly and Company  
Patent Division/SGD  
Lilly Corporate Center  
Indianapolis, Indiana 46285.

#### ASSIGNMENT

☒ Recorded in PTO on December 1, 1997

Reel 8846  
Frame 135

☐ Assignment being submitted separately

ELI LILLY AND COMPANY

By:



Robert A. Armitage  
Vice President and Patent Counsel  
Phone: 317-433-5499

Eli Lilly and Company  
Patent Division/RAA  
Lilly Corporate Center  
Indianapolis, Indiana 46285

---

BEST AVAILABLE COPY